Journal article icon

Journal article

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Abstract:

Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α (TNFα) inhibitors.

Methods: BE COMPLETE was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial conducted acro...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S0140-6736(22)02303-0

Authors


Publisher:
Elsevier
Journal:
Lancet More from this journal
Volume:
401
Issue:
10370
Pages:
38-48
Publication date:
2022-12-06
Acceptance date:
2022-11-03
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Language:
English
Keywords:
Pubs id:
1300482
Local pid:
pubs:1300482
Deposit date:
2022-11-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP